Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Skye Bioscience Inc SKYE

Healthcare Biotechnology
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation... see more

Recent & Breaking News (NDAQ:SKYE)

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion

Newsfile February 2, 2023

Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort

Newsfile January 31, 2023

Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion

Newsfile January 27, 2023

Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE

Newsfile December 20, 2022

Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

Newsfile December 16, 2022

Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer

Newsfile December 13, 2022

Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference

Newsfile November 22, 2022

Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA

Newsfile November 17, 2022

Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100

Newsfile November 16, 2022

EMERALD HEALTH SCIENCES INC. - EARLY WARNING NEWS RELEASE

Canada NewsWire November 11, 2022

Skye Bioscience Closes Acquisition of Emerald Health Therapeutics

Newsfile November 10, 2022

Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement

Newsfile November 7, 2022

Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.

Newsfile September 30, 2022

Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

GlobeNewswire September 20, 2022

Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date

GlobeNewswire September 1, 2022

Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience

Newsfile August 26, 2022

Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye

GlobeNewswire August 19, 2022

Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience

Newsfile August 12, 2022

Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer

GlobeNewswire July 21, 2022

Skye Bioscience Updates Phase 1 Timeline

GlobeNewswire July 20, 2022